Key Points
- Director John Turman Fleming sold 2,450 shares of USANA Health Sciences for about $43,928.50, cutting his stake by 36.68% and leaving him with 4,230 shares.
- USANA shares were little changed after the disclosure, opening at $18.26, near their 50-day average of $18.33 and below the 200-day average of $19.46.
- The company recently beat quarterly earnings and revenue estimates, but analysts remain cautious, with a consensus rating of "Reduce" following recent downgrades.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director John Turman Fleming sold 2,450 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director owned 4,230 shares of the company's stock, valued at $75,843.90. The trade was a 36.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
USANA Health Sciences Stock Down 0.2%
USNA opened at $18.26 on Tuesday. The stock has a fifty day moving average of $18.33 and a 200-day moving average of $19.46. The firm has a market capitalization of $337.12 million, a P/E ratio of 38.86, a PEG ratio of 0.72 and a beta of 0.77. USANA Health Sciences, Inc. has a 12-month low of $16.60 and a 12-month high of $38.32.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, analysts expect that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On USANA Health Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Empowered Funds LLC grew its position in shares of USANA Health Sciences by 9.7% in the first quarter. Empowered Funds LLC now owns 66,293 shares of the company's stock valued at $1,158,000 after purchasing an additional 5,856 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of USANA Health Sciences in the first quarter valued at about $1,265,000. Sei Investments Co. grew its position in shares of USANA Health Sciences by 98.8% in the first quarter. Sei Investments Co. now owns 59,730 shares of the company's stock valued at $1,043,000 after purchasing an additional 29,691 shares during the last quarter. State of Wyoming acquired a new stake in shares of USANA Health Sciences in the first quarter valued at about $57,000. Finally, First Trust Advisors LP grew its position in USANA Health Sciences by 17.7% during the first quarter. First Trust Advisors LP now owns 14,784 shares of the company's stock worth $258,000 after buying an additional 2,227 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on USNA. Wall Street Zen lowered USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a report on Friday, March 27th. Finally, Zacks Research lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Reduce".
View Our Latest Research Report on USNA
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
